The Influence of Cancer Stem Cells on the Risk of Relapse in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Prospective Cohort Study.
cancer stem cells
early stages
locally advanced stage
non–small cell lung cancer
relapse
Journal
Stem cells translational medicine
ISSN: 2157-6580
Titre abrégé: Stem Cells Transl Med
Pays: England
ID NLM: 101578022
Informations de publication
Date de publication:
31 03 2022
31 03 2022
Historique:
received:
28
05
2021
accepted:
26
11
2021
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
8
4
2022
Statut:
ppublish
Résumé
Lung cancer relapse may be associated with the presence of a small population of cancer stem cells (CSCs) with unlimited proliferative potential. Our study assessed the relationship between CSCs and the relapse rate in patients harboring adenocarcinoma (ADL) and squamous cell carcinoma of the lung (SCCL). This is an observational prospective cohort study (NCT04634630) assessing the influence of CSC frequency on relapse rate after major lung resection in 35 patients harboring early (I-II) (n = 21) and locally advanced (IIIA) (n = 14) ADL and SCCL. There was a 2-year enrollment period followed by a 1-year follow-up period. Surgical tumor specimens were processed, and CSCs were quantified by cytofluorimetric analysis. Cancer stem cells were expressed in all patients with a median of 3.1% of the primary cell culture. Primary analysis showed no influence of CSC frequency on the risk of relapse (hazard ratio [HR] = 1.05, 95% confidence interval [CI] = 0.85-1.30). At secondary analysis, patients with locally advanced disease with higher CSC frequency had an increased risk of relapse (HR = 1.26, 95% CI = 1.14-1.39), whereas this was not observed in early-stage patients (HR = 0.90, 95% CI = 0.65-1.25). No association was found between CSC and relapse rates after major lung resection in patients harboring ACL and SCCL. However, in locally advanced-stage patients, a positive correlation was observed between CSC frequency and risk of relapse. These results indicate a need for further molecular investigations into the prognostic role of CSCs at different lung cancer stages. NCT04634630.
Identifiants
pubmed: 35356974
pii: 6534985
doi: 10.1093/stcltm/szab029
pmc: PMC8968653
doi:
Banques de données
ClinicalTrials.gov
['NCT04634630']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-247Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Br J Cancer. 2020 Dec;123(Suppl 1):3-9
pubmed: 33293670
J Thorac Dis. 2014 May;6 Suppl 2:S217-23
pubmed: 24868439
J Comp Eff Res. 2018 Aug;7(8):765-773
pubmed: 30132371
J Pathol. 2010 Dec;222(4):335-44
pubmed: 20848663
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Diagnostics (Basel). 2020 Mar 06;10(3):
pubmed: 32155787
Clin Exp Med. 2017 May;17(2):131-139
pubmed: 26886278
PLoS Comput Biol. 2016 Mar 10;12(3):e1004747
pubmed: 26963104
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Front Oncol. 2020 Oct 09;10:575472
pubmed: 33163406
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):348-57
pubmed: 15667952
Oncotarget. 2020 Feb 04;11(5):550-559
pubmed: 32082488
Cancers (Basel). 2011 Aug 12;3(3):3279-330
pubmed: 24212956
Cell Cycle. 2008 May 15;7(10):1360-70
pubmed: 18418062
J Clin Med. 2020 Jun 15;9(6):
pubmed: 32549358
Mol Cancer Res. 2009 Mar;7(3):330-8
pubmed: 19276181
Oncotarget. 2020 Apr 28;11(17):1545-1555
pubmed: 32391123
Front Oncol. 2019 Dec 18;9:1394
pubmed: 31921651
Diagnostics (Basel). 2020 Dec 15;10(12):
pubmed: 33333743
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Microarrays (Basel). 2013 Dec 13;2(4):318-39
pubmed: 27605195
BMC Cancer. 2011 Jun 27;11:275
pubmed: 21708005
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
J Thorac Oncol. 2015 Jan;10(1):67-73
pubmed: 25396679
J Egypt Natl Canc Inst. 2020 Nov 2;32(1):41
pubmed: 33135114
Biochem J. 2018 May 9;475(9):1611-1634
pubmed: 29743249
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Cell Commun Signal. 2021 Feb 15;19(1):19
pubmed: 33588867
Transl Lung Cancer Res. 2015 Dec;4(6):689-703
pubmed: 26798578
Curr Stem Cell Res Ther. 2008 Dec;3(4):237-46
pubmed: 19075754
Cancer Res. 2010 Dec 1;70(23):9937-48
pubmed: 21118965
Cancers (Basel). 2017 Jan 24;9(2):
pubmed: 28125017
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Heart Lung Circ. 2015 Aug;24(8):780-8
pubmed: 25921687
J Thorac Oncol. 2016 Jul;11(7):964-75
pubmed: 27117833
Oncotarget. 2017 Aug 3;8(42):72544-72563
pubmed: 29069808
Cancer Biol Med. 2016 Mar;13(1):3-11
pubmed: 27144058
BMC Med. 2016 May 05;14:73
pubmed: 27151159
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
JAMA Oncol. 2017 Nov 01;3(11):1529-1537
pubmed: 28687838
Thorax. 2009 Mar;64(3):192-6
pubmed: 19252018
Cancer Lett. 2015 Dec 1;369(1):50-7
pubmed: 26319899
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Stem Cell Rev Rep. 2019 Jun;15(3):331-355
pubmed: 30993589
Clin Lung Cancer. 2016 Sep;17(5):350-361
pubmed: 27137346
JAMA Netw Open. 2019 Nov 1;2(11):e1915724
pubmed: 31747032
Anticancer Res. 2012 Sep;32(9):3953-60
pubmed: 22993343
Trends Cancer. 2020 May;6(5):432-441
pubmed: 32348738
Oncol Lett. 2014 Apr;7(4):1300-1304
pubmed: 24944713
Stem Cells Int. 2019 Jan 13;2019:3904645
pubmed: 30733805
Adv Ther. 2019 Apr;36(4):766-785
pubmed: 30864106
Eur Respir J. 2016 Feb;47(2):374-8
pubmed: 26828046
Pak J Biol Sci. 2018;21(3):135-150
pubmed: 30187723
Front Oncol. 2021 Mar 31;11:613198
pubmed: 33868998
Clin Exp Metastasis. 2016 Jan;33(1):97-113
pubmed: 26445849
Front Mol Biosci. 2020 Apr 30;7:79
pubmed: 32426371
Cancers (Basel). 2019 Aug 22;11(9):
pubmed: 31443496
Drug Discov Today. 2014 Dec;19(12):1953-63
pubmed: 25256776
Cancer Res. 2010 Feb 15;70(4):1469-78
pubmed: 20145124
Clin Transl Med. 2018 Mar 1;7(1):11
pubmed: 29541939
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711